Brian is an award-winning entrepreneur and technology executive. He has been recognized nationally and locally for his achievements, having founded and led some of the fastest growing technology companies in North America - ranked in the Deloitte Technology Fast 500 and the Inc. 500. The Baltimore Sun selected Brian as one of five "Earthly Angels" for his positive impact. He was chosen as the 2016 Emerging Technology Company CEO of the Year by OCTANe, as a 2016 Excellence in Entrepreneurship Winner from the Orange County Business Journal, and a 2-time finalist for the EY Entrepreneur of the Year Award. Previously, Brian was a Team Leader at the e.Lilly venture fund, a division of Eli Lilly, former manager of digital health for Johnson & Johnson’s largest product, and helped direct marketing efforts for Prometheus Laboratories. As a pioneer in big data and precision medicine, he founded and was CEO of Proove Biosciences which created the world’s largest clinical-genetics in chronic pain database of over 150,000 patients. Today, Brian is Managing Partner of social impact investment group, Profound Ventures, and serves as an interim executive for several of its portfolio companies.
AI and Data Sciences Showcase:
Bennufit operates a clinical analytics platform focused on solving the dueling health crises of chronic pain and opioid use disorder (OUD) by harnessing the power of AI to assess behavioral, lifestyle, environmental, demographic, genetic, wearable, medical device, and laboratory data.
How Data Science And Predictive Analytics Can Help Solve The Opioid Abuse Crisis
This talk will explain how precision medicine can be applied in chronic pain and opioid abuse, with specific examples of algorithm-derived genetic tests, lessons learned from the world's largest clinical-genetic biobank for chronic pain, and published clinical validity and utility data to support such technology.
The PMWC 2020 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.